United States - English - NLM (National Library of Medicine)

stratus pharamceuticals, inc - lactic acid (unii: 33x04xa5at) (lactic acid - unii:33x04xa5at) - lactic acid 11.34 g in 113.4 g

United States - English - NLM (National Library of Medicine)

stratus pharamceuticals, inc - lactic acid (unii: 33x04xa5at) (lactic acid - unii:33x04xa5at) - lactic acid 35.484 ml in 354.84 ml

United States - English - NLM (National Library of Medicine)

acella pharmaceuticals - urea (unii: 8w8t17847w) (urea - unii:8w8t17847w) - urea 35 g in 100 g - indications and usage for enzymatic debridement and promotion of normal healing of surface lesions, particularly where healing is retarded by local infection, necrotic tissue, fibrinous or purulent debris, or eschar. topically applied urea is useful for the treatment of hyperkeratotic conditions such as dermatitis, psoriasis, xerosis, ichthyosis, eczema, keratosis, keratoderma, and dry, rough skin, as well as corns and calluses and damaged, ingrown and devitalized nails. contraindications known hypersensitivity to any of the listed ingredients.

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - hydroxyurea (unii: x6q56qn5qc) (hydroxyurea - unii:x6q56qn5qc) - hydroxyurea 500 mg - significant tumor response to hydroxyurea capsules usp has been demonstrated in melanoma, resistant chronic myelocytic leukemia, and recurrent, metastatic, or inoperable carcinoma of the ovary. hydroxyurea, usp used concomitantly with irradiation therapy is intended for use in the local control of primary squamous cell (epidermoid) carcinomas of the head and neck, excluding the lip. hydroxyurea is contraindicated in patients with marked bone marrow depression, i.e., leukopenia (< 2500 wbc) or thrombocytopenia (< 100,000), or severe anemia. hydroxyurea capsules are contraindicated in patients who have demonstrated a previous hypersensitivity to hydroxyurea or any other component of its formulation.

United States - English - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - hydroxyurea (unii: x6q56qn5qc) (hydroxyurea - unii:x6q56qn5qc) - hydroxyurea 500 mg - hydroxyurea capsules are indicated for the treatment of: - resistant chronic myeloid leukemia. - locally advanced squamous cell carcinomas of the head and neck (excluding the lip) in combination with chemoradiation. hydroxyurea is contraindicated in patients who have demonstrated a previous hypersensitivity to hydroxyurea or any other component of the formulation. risk summary hydroxyurea capsules can cause fetal harm based on findings from animal studies and the drug’s mechanism of action [see clinical pharmacology (12.1)] . there are no data with hydroxyurea capsules use in pregnant women to inform a drug-associated risk. in animal reproduction studies, administration of hydroxyurea to pregnant rats and rabbits during organogenesis produced embryotoxic and teratogenic effects at doses 0.8 times and 0.3 times, respectively, the maximum recommended human daily dose on a mg/m2 basis (see data) . advise women of the potential risk to a fetus and to avoid becoming pregnant while being treated with hydroxyurea c

United States - English - NLM (National Library of Medicine)

par pharmaceutical, inc. - hydroxyurea (unii: x6q56qn5qc) (hydroxyurea - unii:x6q56qn5qc) - hydroxyurea 500 mg - hydroxyurea capsules, usp is indicated for the treatment of: - resistant chronic myeloid leukemia. - locally advanced squamous cell carcinomas of the head and neck (excluding the lip) in combination with chemoradiation. hydroxyurea capsules are contraindicated in patients who have demonstrated a previous hypersensitivity to hydroxyurea or any other component of the formulation. risk summary hydroxyurea capsules can cause fetal harm based on findings from animal studies and the drug’s mechanism of action [see clinical pharmacology (12.1) ]. there are no data with hydroxyurea capsules use in pregnant women to inform a drug-associated risk. in animal reproduction studies, administration of hydroxyurea to pregnant rats and rabbits during organogenesis produced embryotoxic and teratogenic effects at doses 0.8 times and 0.3 times, respectively, the maximum recommended human daily dose on a mg/m2 basis (see data ). advise women of the potential risk to a fetus and to avoid becoming pregnant while being treated with

United States - English - NLM (National Library of Medicine)

american health packaging - hydroxyurea (unii: x6q56qn5qc) (hydroxyurea - unii:x6q56qn5qc) - hydroxyurea 500 mg - hydroxyurea capsules are indicated for the treatment of: - resistant chronic myeloid leukemia. - locally advanced squamous cell carcinomas of the head and neck (excluding the lip) in combination with chemoradiation. hydroxyurea capsules are contraindicated in patients who have demonstrated a previous hypersensitivity to hydroxyurea or any other component of the formulation. risk summary hydroxyurea capsules can cause fetal harm based on findings from animal studies and the drug’s mechanism of action [see clinical pharmacology (12.1)]. there are no data with hydroxyurea capsules use in pregnant women to inform a drug-associated risk. in animal reproduction studies, administration of hydroxyurea to pregnant rats and rabbits during organogenesis produced embryotoxic and teratogenic effects at doses 0.8 times and 0.3 times, respectively, the maximum recommended human daily dose on a mg/m 2 basis (see data). advise women of the potential risk to a fetus and to avoid becoming pregnant while be

United States - English - NLM (National Library of Medicine)

cardinal health 107, llc - hydroxyurea (unii: x6q56qn5qc) (hydroxyurea - unii:x6q56qn5qc) - hydroxyurea 500 mg - hydroxyurea capsules, usp is indicated for the treatment of: hydroxyurea capsules are contraindicated in patients who have demonstrated a previous hypersensitivity to hydroxyurea or any other component of the formulation. risk summary hydroxyurea capsules can cause fetal harm based on findings from animal studies and the drug’s mechanism of action [see clinical pharmacology (12.1)]. there are no data with hydroxyurea capsules use in pregnant women to inform a drug-associated risk. in animal reproduction studies, administration of hydroxyurea to pregnant rats and rabbits during organogenesis produced embryotoxic and teratogenic effects at doses 0.8 times and 0.3 times, respectively, the maximum recommended human daily dose on a mg/m 2 basis (see data). advise women of the potential risk to a fetus and to avoid becoming pregnant while being treated with hydroxyurea capsules. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically

United States - English - NLM (National Library of Medicine)

avkare - hydroxyurea (unii: x6q56qn5qc) (hydroxyurea - unii:x6q56qn5qc) - hydroxyurea 500 mg - hydroxyurea capsules are indicated for the treatment of: - resistant chronic myeloid leukemia. - locally advanced squamous cell carcinomas of the head and neck (excluding the lip) in combination with chemoradiation. hydroxyurea is contraindicated in patients who have demonstrated a previous hypersensitivity to hydroxyurea or any other component of the formulation. risk summary hydroxyurea capsules can cause fetal harm based on findings from animal studies and the drug’s mechanism of action [see clinical pharmacology ( 12.1)] . there are no data with hydroxyurea capsules use in pregnant women to inform a drug-associated risk. in animal reproduction studies, administration of hydroxyurea to pregnant rats and rabbits during organogenesis produced embryotoxic and teratogenic effects at doses 0.8 times and 0.3 times, respectively, the maximum recommended human daily dose on a mg/m 2 basis (see data). advise women of the potential risk to

United States - English - NLM (National Library of Medicine)

golden state medical supply, inc. - hydroxyurea (unii: x6q56qn5qc) (hydroxyurea - unii:x6q56qn5qc) - hydroxyurea 500 mg - hydroxyurea capsules, usp is indicated for the treatment of: - resistant chronic myeloid leukemia. - locally advanced squamous cell carcinomas of the head and neck (excluding the lip) in combination with chemoradiation. hydroxyurea capsules are contraindicated in patients who have demonstrated a previous hypersensitivity to hydroxyurea or any other component of the formulation. risk summary hydroxyurea capsules can cause fetal harm based on findings from animal studies and the drug’s mechanism of action [see  clinical pharmacology (12.1) ]. there are no data with hydroxyurea capsules use in pregnant women to inform a drug-associated risk. in animal reproduction studies, administration of hydroxyurea to pregnant rats and rabbits during organogenesis produced embryotoxic and teratogenic effects at doses 0.8 times and 0.3 times, respectively, the maximum recommended human daily dose on a mg/m 2 basis ( see data ). advise women of the potential risk to a fetus and to avo